Cysteine engineered fibronectin type III domain binding molecules

US10662235B2 · kind B2 · utility

Assignee

• JANSSEN BIOTECH, INC. · US

Inventors

• Mark Anderson · Norristown, US
• Ricardo Attar · Lawrenceville, US
• Michael Diem · Havertown, US
• Linus Hyun · Radnor, US
• Alastair King · Norristown, US
• Steven Jacobs · North Wales, US
• Shalom Goldberg · Cynwyd Estates, US
• Donna Klein · Philadelphia, US
• Sheri Moores · Phoenixville, US
• Karyn O'Neil · Spring House, US
• Kristen Picha · Malvern, US

Key dates

• Filing date: Jun 21, 2017
• Grant date: May 26, 2020
• Expiry date: Jul 5, 2037

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/74
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Cysteine engineered monospecific and bispecific EGFR and/or c-Met FN3 domain containing molecules comprising one or more free cysteine amino acids are prepared by mutagenizing a nucleic acid sequence of a parent molecule and replacing one or more amino acid residues by cysteine to encode the cysteine engineered FN3 domain containing monospecific or bispecific molecules; expressing the cysteine engineered FN3 domain containing molecules; and recovering the cysteine engineered FN3 domain containing molecule. Isolated cysteine engineered monospecific or bispecific FN3 domain containing molecules may be covalently attached to a detection label or a drug moiety and used therapeutically.